Abbott Laboratories | Mega-cap | Healthcare
$136.26
0.18%
| Abbott Laboratories Stock Comparison:
Abbott Laboratories vs Boston ScientificAbbott Laboratories vs StrykerAbbott Laboratories vs Medtronic plcAbbott Laboratories vs Edwards LifesciencesAbbott Laboratories vs DexcomAbbott Laboratories vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 42.0B
Gross Profit 23.2B 55.41%
Operating Income 6.8B 16.27%
Net Income 13.4B 31.95%
EPS (Diluted) $7.64

Balance Sheet Metrics

Total Assets 81.4B
Total Liabilities 33.5B
Shareholders Equity 47.9B
Debt to Equity 0.70

Cash Flow Metrics

Operating Cash Flow 16.9B
Free Cash Flow 6.4B

Revenue & Profitability Trend

Abbott Laboratories Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 42.0B 40.1B 43.7B 43.1B 34.6B
Cost of Goods Sold 18.7B 18.0B 19.1B 18.5B 15.0B
Gross Profit 23.2B 22.1B 24.5B 24.5B 19.6B
Research & Development 2.8B 2.7B 2.9B 2.7B 2.4B
Selling, General & Administrative 11.7B 10.9B 11.2B 11.3B 9.7B
Other Operating Expenses 1.9B 2.0B 2.0B 2.0B 2.1B
Total Operating Expenses 16.4B 15.7B 16.1B 16.1B 14.2B
Operating Income 6.8B 6.5B 8.4B 8.4B 5.4B
Pre-tax Income 7.0B 6.7B 8.3B 8.2B 5.0B
Income Tax -6.4B 941.0M 1.4B 1.1B 497.0M
Net Income 13.4B 5.7B 6.9B 7.1B 4.5B
EPS (Diluted) $7.64 $3.26 $3.91 $3.94 $2.50

Income Statement Trend

Abbott Laboratories Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 23.7B 22.7B 25.2B 24.2B 20.4B
Non-Current Assets 57.8B 50.5B 49.2B 51.0B 52.1B
Total Assets 81.4B 73.2B 74.4B 75.2B 72.5B
Liabilities
Current Liabilities 14.2B 13.8B 15.5B 13.1B 11.9B
Non-Current Liabilities 19.4B 20.5B 22.0B 26.1B 27.6B
Total Liabilities 33.5B 34.4B 37.5B 39.2B 39.5B
Equity
Total Shareholders Equity 47.9B 38.8B 36.9B 36.0B 33.0B

Balance Sheet Composition

Abbott Laboratories Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 13.4B 5.7B 6.9B 7.1B 4.5B
Operating Cash Flow 16.9B 7.7B 9.4B 10.8B 8.7B
Investing Activities
Capital Expenditures -2.2B -2.2B -1.8B -1.9B -2.2B
Investing Cash Flow -2.3B -3.1B -1.7B -2.0B -2.2B
Financing Activities
Dividends Paid -3.8B -3.6B -3.3B -3.2B -2.6B
Financing Cash Flow -5.7B -7.3B -7.8B -5.7B -3.0B
Free Cash Flow 6.4B 5.1B 7.8B 8.6B 5.7B

Cash Flow Trend

Abbott Laboratories Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 17.31
Forward P/E 25.83
Price to Book 4.75
Price to Sales 5.48
PEG Ratio 25.83

Profitability Ratios

Profit Margin 31.89%
Operating Margin 18.09%
Return on Equity 30.65%
Return on Assets 6.38%

Financial Health

Current Ratio 1.78
Debt to Equity 27.09
Beta 0.74

Per Share Data

EPS (TTM) $7.70
Book Value per Share $28.06
Revenue per Share $24.34

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
abt 231.9B 17.31 4.75 30.65% 31.89% 27.09
Boston Scientific 149.9B 73.94 6.75 9.50% 11.58% 52.16
Stryker 148.0B 52.39 7.07 14.26% 12.31% 82.92
Medtronic plc 110.3B 23.84 2.30 9.51% 13.90% 61.39
Edwards Lifesciences 43.3B 30.51 4.27 16.51% 75.71% 6.86
Dexcom 31.3B 60.03 13.81 23.72% 12.90% 113.97

Financial data is updated regularly. All figures are in the company's reporting currency.